Environmental Toxins and Parkinson’s Disease

Parkinson's Disease

Volumn , Issue , 2004, Pages 51-62

  Ratner, Marcia H ^a   Feldman, Robert G ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85045146836     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-16     Document Type: Chapter

References (125)

1. Calne, D. B., Peppard, R. F., Aging of the nigrostriatal pathway in humans, Can. J. Neurol. Sci., 14(3 Suppl):424-7, 1987.
2. Doraiswamy, P. M., Na, C., Husain, M. M., Figiel, G. S., McDonald, W. M., Ellinwood, Jr., E. H., Boyko, O. B., Krishnan, K.R., Morphometric changes of the human midbrain with normal aging: MR and stereologic findings. AJNR Am. J. Neuroradiol., 13(1):383-386, 1992.
3. Pollack, M., Leeuwenburgh, C., Apoptosis and aging: Role of the mitochondria. J. Gerontol. A. Biol. Sci. Med. Sci., (11):B475-82, 2001.
4. Duan, W, and Mattson, M. P., Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson’s disease. J. Neurosci. Res., 57(2):195-206, 1999.
5. Casadesus, G., Shukitt-Hale, B., Joseph, J. A., Qualitative versus quantitative caloric intake: Are they equivalent paths to successful aging? Neurobiol. Aging, 23(5):747-69, 2002.
6. Sreekumar, R., Unnikrishnan, J., Fu, A., Nygren, J., Short, K. R., Schimke, J., Barazzoni, R., Nair, K. S., Effects of caloric restriction on mitochondrial function and gene transcripts in rat muscle, Am. J. Physiol. Endocrinol Metab., (1):E38-43, 2002.
7. Chen, S. K., Hsieh, W. A., Tsai, M. H., Chen, C. C., Hong, A. I., Wei, Y. H., Chang, W. P., Age-associated decrease of oxidative repair enzymes, human 8-oxoguanine DNA glycosylases (hOgg1), in human aging, J. Radiat. Res. (Tokyo), 44(1):31-35, 2003.
8. Mattson, M. P., Duan, W., Guo, Z., Meal size and frequency affect neuronal plasticity and vulnerability to disease: Cellular and molecular mechanisms, J. Neurochem, 84(3):417-31, 2003.
9. Rajput, A. H., Uitti, R. J., Stern, W., Laverty, W., O’Donnell, K., O’Donnell, D., Yuen, W. K., Dua. Geography drinking water chemistry, pesticides and herbicides and the etiology of Parkinson’s disease, Can. J. Neurol. Sci., 14(3 Suppl):414-418, 1987.
10. Zhang, Z. X., and Roman, G. C., Worldwide occurrence of Parkinson’s disease: An updated review, Neuroepidemiol, 12:195-208, 1993.
11. Bharucha, E. P., Bharucha, N.E., Epidemiological study of Parkinson’s disease in Parsis in India, Adv. Neurol., 60:352-354, 1993.
12. Mayeux, R., Marder, K., Cote, L. J., Denaro, J., Hemenegildo, N., Mejia, H., Tang, M. X., Lantigua, R., Wilder, D., Gurland, B. et al, The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988-1993, Am. J. Epidemiol., 142:820-827, 1995.
13. Tandberg, E., Larsen, J. P., Nessler, E. G., Riise, T., Aarli, J. A., The epidemiology of Parkinson’s disease in the county of Rogaland, Norway, Mov. Disord., 10:541-549, 1995.
14. Sutcliffe, R. L., Meara, J. R., Parkinson’s disease epidemiology in the Northampton District, England, 1992, Acta Neurol. Scand., 92:443-450, 1995.
15. Koller, W., Vetere-Overfield, B., Gray, C., Alexander, C., Chin, T., Dolezal, J., Hassanein, R., Tanner, C., Environmental risk factors in Parkinson’s disease, Neurology, 40(8):1218-1221, 1990.
16. Imaizumi, Y., Kaneko, R., Rising mortality from Parkinson’s disease in Japan, 1950-1992, Acta Neurol. Scand. 91:169-176, 1995.
17. Martilla, R. J., Epidemiology of Parkinson’s disease, In: Koller WC (ed); Handbook of Parkinson’s Disease. New York, Marcel Dekker, pp. 35-50, 1989.
18. Dodel, R. C., Eggert, K. M, Singer, M. S., Eichhorn, T. E., Pogarell, O., Oertel W. H., Costs of drug treatment in Parkinson’s disease, Mov. Disord., 13:249-254, 1998.
19. Sloane, P. D., Zimmerman, S., Suchindran, C., Reed, P., Wang, L., Boustani, M., Sudha, S., The public health impact of Alzheimer’s disease, 2000-2050: Potential implication of treatment advances, Annu. Rev. Public Health, 23:213-231, 2002.
20. Seidler, A., Hellenbrand, W., Robra, B. P., Vieregge, P., Nischan, P., Joerg, J., Oertel, W. H., Ulm, G., Schneider, E., Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: A case-control study in Germany, Neurology, 46(5):1275-1284, 1996.
21. Feldman, R.G., and Ratner, M. H., The pathogenesis of neurodegenerative disease: Neurotoxic mechanisms of action and genetics, Current Opinion in Neurology, 12:725-731, 1999.
22. Goble, L. I., The genetics of Parkinson’s disease, Rev. Neurosci., 4:1-16, 1993.
23. Lazzarini, A. M., Myers, R. H., Zimmerman, T. R., Mark, M. H., Golbe, L. I., Sage, J. I., Johnson, W. G., Duvoisin, R. C., A clinical genetic study of Parkinson’s disease: Evidence for dominant transmission, Neurology, 44:499-506, 1994.
24. Tanner, C. M., Chen, B., Wang, W., Peng, M., Liu, Z., Liang X., Kao, L. C., Gilley, D. W., Goetz, C. G., Schoenberg, B. S., Environmental factors and Parkinson’s disease: A case-control study in China, Neurology, 39(5):660-664, 1989.
25. Oliveira, S. A., Scott, W. K., Martin, E. R., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Pahwa, R., Stern, M. B., Hiner, B. C., Ondo, W. G., Allen, F. H., Jr., Scott, B. L., Goetz, C. G., Small, G. W., Mastaglia, F., Stajich, J. M., Zhang, F., Booze, M. W., Winn, M. P., Middleton, L. T., Haines, J. L., Pericak-Vance, M. A., Vance, J. M., Parkin mutations and susceptibility alleles in late-onset Parkinson’s disease, Ann. Neurol., 53(5):624-629, 2003.
26. DeStefano, A. L., Lew, M. F., Golbe, L. I., Mark, M. H., Lazzarini, A. M., Guttman, M., Montgomery, E., Waters, C. H., Singer, C., Watts, R. L., Currie, L. J., Wooten, G. F., Maher, N. E., Wilk, J. B., Sullivan, K. M., Slater, K. M., Saint-Hilaire, M. H., Feldman, R. G., Suchowersky, O., Lafontaine, A. L., Labelle, N., Growdon, J. H., Vieregge, P., Pramstaller, P. P, Klein, C., Hubble, J. P., Reider, C. R., Stacy, M., MacDonald, M. E., Gusella, J. F., Myers, R. H., PARK3 influences age at onset in Parkinson disease: A genome scan in the GenePD study, Am. J. Hum. Genet., 70(5):1089-1095, 2002.
27. Feldman, R. G., and Ratner, M. H., Essentials of Metal Neurotoxicity: Mechanisms and Pathology. Clinics in Occupational and Environmental Medicine, Neurotoxicology, 1(3):1526-1546, 2001.
28. Ratner, M., Cabello, D., Thaler, D., and Feldman, R., Movement disorder in an adult following exposure to DEET, J. Toxicol. Clin. Toxicol., 39: 477, 2001.
29. Barbosa, ER., Comerlatti, L. R., Haddad, M. S., Scaff, M., Parkinsonism secondary to ethylene oxide exposure: Case report, Arq. Neuropsiquiatr. 50(4):531-3, 1992.
30. Pezzoli, G., Antonini, A., Barbieri, S., Canesi, M., Perbellini, L., Zecchinelli, A., Mariani, C. B., Bonetti, A., and Leenders, K. L., n-Hexane-induced parkinsonism: Pathogenetic hypotheses, Mov. Disord., 10:279-282, 1995.
31. Liou, H. H., Tsai, M. C., Chewn, C. J., Jeng, J. S., Chang, Y. C., Chen, S. Y., Chen, R. C., Environmental risk factors and Parkinson’s disease: A case-control study in Taiwan, Neurology, 48:1583-1588, 1997.
32. Kim, Y., Kim, J. W., Ito, K., Lim, H. S., Cheong, H. K., Kim, J. Y., Shin, Y. C., Kim, K. S., Moon, Y., Idiopathic parkinsonism with superimposed manganese exposure: Utility of positron emission tomography, Neurotoxicolog, 20(2-3):249-52, 1999.
33. Seppäläinen, A. M., and Haltia, M., 1980, Carbon disulfide, in Spencer PS, and Schaumburg HH (eds); Experimental and Clinical Neurotoxicology, Williams and Wilkins, Baltimore/London, pp. 356-373, 1980.
34. Laplane, D., Attal, N., Sauron, B., de Billy, A., and Dubois, B., Lesions of basal ganglia due to disulfiram neurotoxicity, J. Neurol. Neurosurg. Psychiatr., 55:925-929, 1992.
35. Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I,: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219:979-980, 1983.
36. Langston, J. W., Forno, L. S., Rebert, C. S., and Irwin, I., Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey, Brain Res. 292:390-394, 1984.
37. Donaldson, J., Manganese and human health, In: Stokes, P. M., Campbell, P. G., Schroeder, W. H., Trick, C., France, R. L., Puckett, K. J., Lazerte, B., Speyer, M., Hanna, J. E., and Donaldson, J. (eds), Manganese in the Canadian Environment, NRCC No. 26193; ISSN 0316-0114. Ottawa, NRCC Associate Committee on Scientific Criteria for Environmental Quality, pp. 93-111, 1988.
38. Gibb, W. R. G., The neuropathology of parkinsonian disorders. Parkinson’s disease and movement disorders, in Jankovic, J., and Tolosa, E., (Eds): Parkinson’s Disease and Movement Disorders, Baltimore-Munich,Urban and Schwartzenberg, pp. 205-223, 1988.
39. Heikkila, R. E., Manzino, L., Cabbat, F. S., and Duvoisin, R. C., Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors, Nature, 311:467-469, 1984.
40. Heikkila, R. E., Cabbat, F. S., and Cohen, G., In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate, J. Biol. Chem., 251:1451-1453, 1976.
41. Walters, T. L., Irwin, I., Delfani, K., Langston, J. W., and Janson, A. M., Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP, Exp. Neurol., 156:62-70, 1999.
42. Shults, C. W., Beal, M. F., Fontaine, D. et al, Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients, Neurology, 50:793-795, 1998.
43. Davey, G. P., Tipton, K. F., and Murphy, M. P., Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion selective electrode, Biochem. Med. J., 288:439-443, 1992.
44. Schapira, A. H., Mann, V. M., Cooper, J. M. et al, Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease, J. Neurochem., 55:2142-2145, 1990.
45. Javitch, J. A., D’Amato, R. J., Strittmatter, S. M., and Snyder, S. H., Parkinsonism inducing neurotoxin, Nmethyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity, Proc. Natl. Acad. Sci., 82:2173-2177, 1985.
46. Nicklas, W. J., Vyas, I., and Heikkila, R. E., Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine, Life Sci., 36:2503-2508, 1985.
47. Ramsey, R. R., and Singer, T. P., Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine, by mitochondri,. 261:7585-7587, 1986.
48. Harley, A., Cooper, J. M., Schapira, A. H., Iron induced oxidative stress and mitochondrial dysfunction: Relevance to Parkinson’s disease, Brain Res. 627:349-353, 1993.
49. Janetsky, B., Hauck, S., Youdim, M. B. H. et al, Unlatered aconitase activity, but decreased complex I acvtivity in substantia pars compacta of patients with Parkinson’s disease, Neurosci. Lett., 169:126-128, 1994.
50. Mann, V. M., Cooper, J. M., Daniel, S. E. et al, Complex I, iron, and ferritin in Parkinson’s disease substantia nigra, Ann. Neurol., 36:876-881, 1994.
51. Reichmann, H., Janetsky, B., and Riederer, P., Irondependent enzymes in Parkinson’s disease, J. Neural. Trans. (Suppl) 46:157-164, 1995.
52. Blake, C. I., Spitz, E., Leehy, M., Hoffer, B. J., and Boyson, S. J., Platelet mitochondrial respiratory chain function in Parkinson’s disease, Mov. Disord., 12:3-8, 1997.
53. Ecobichon, D., Pesticides, in Klaassen C.D. (Ed.), Casarett and Doull’s Toxicology: The Basic Science of Poisons, 5th Ed. McGraw-Hill, N.Y., pp. 671-675, 1996.
54. Di Llio, C., Sacchetta, P., Iannarelli, V., and Aceto, A., Binding of pesticides to alpha, mu and pi class glutathione transferase, Toxicol. Lett., 76:173-177, 1995.
55. Brooks, A. L., Chadwick, C. A., Gelbard, H. A., Cory-Sclechta, D. A., Federoff, H. J., Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss, Brain Res., 823:1-10, 1999.
56. Barbeau, A., Roy, M., Bernier, G., Campanella, G., Paris, S., Ecogenetics of Parkinson’s disease: Prevalence and environmental aspects in rural areas, Can. J. Neurol. Sci., 14:36-41, 1987.
57. Hurley, L. S., Teratogenic aspects of manganese, zinc, and copper nutrition, Physiol. Rev., 61:249-295, 1981
58. Feldman, R. G., Occupational and Environmental Neurotoxicology. Lippincott-Raven, Philadelphia, P.A., 1999.
59. Flinn, R. H., Neal, P. A., Reinhart, W. H., D’Allavalle, J. M., Fulton, W. B., and Dooley, A. E., Chronic manganese poisoning in an ore crushing mill. Public Health Bulletin. No. 247. U.S. Government Printing Office, Washington, D.C., pp. 1-77, 1940.
60. Huang, C. P., and Quist, G. C., The dissolution of manganese ore in dilute aqueous solution, Environ. Int., 9:379-389, 1983.
61. Saric, M., Manganese, in Friberg, L., Nordberg, G. F., and Vouk, V., (Eds.): Handbook on the Toxicology of Metals, 2nd ed. Elsevier, Amsterdam, pp. 354-386, 1986.
62. Sjogren, B., Ingren, A., Frech, W., Hagman, M., Johansson, L., Tesarz, M., and Wennberg, A., Effects on the nervous system among welders exposed to aluminum and manganese, Occup. Environ. Med., 53(1):32-40, 1996.
63. Sittig, W., Kleindienst, G., and Irmisch, R., Effects of food intake on CNS activity. psychomotor performance and mood states in healthy volunteers, Pharmacopsychiat., 18(1):123-126, 1985.
64. Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth, W. T., Jr., Swanson, P. D., Checkoway, H., Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes, Neurology, 10;60(11):1761-1766, 2003.
65. Hauser, R. A., Zesiewicz, T. A., Rosemurgy, A. S. et al, Manganese intoxication and chronic liver failure, Ann. Neurol., 36:871-875, 1994.
66. Cotzias, G. C., Manganese in health and disease, Physiol. Rev., 38:503-532, 1958.
67. Maynard, L. S., and Cotzias, G. C., Partition of manganese among organs and intracellular organelles of the rat, J. Biol. Chem., 214:489-495, 1955.
68. Kono, Y., Takahashi, M., Asada, K., Oxidation of manganous pyrophosphate by superoxide radicals and illuminated spinach chloroplasts, Arch. Biochem. Biophys., 174:454-461, 1976.
69. Graham, D. G., Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones, Mol. Pharmacol., 14:633-643, 1978.
70. Graham, D. G., Tiffany, S. M., Bell, W. R., and Gutknecht, W. F., Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds towards C1300 neuroblastoma cells in vitro, Mol. Pharmacol., 14:644-653, 1978.
71. Donaldson, J., LaBella, F. S., and Gesser, D., Enhanced autoxidation of dopamine as a possible basis of manganese neurotoxicity, Neurotoxicol., 2:53-64, 1980.
72. World Health Organization (WHO), Manganese, Environmental Health Criteria, Geneva, 17:1-110, 1981.
73. Halliwell, B., Manganese ions, oxidation reactions and the superoxide radical, Neurotoxicology, 5(1):113-118, 1984.
74. Lydén, A., Larsson, B. S., and Lindquist, N. G., Melanin affinity of manganese, Acta Pharmaco. et Teratol., 55:133-138, 1984.
75. Hintz, P., and Kalyaraman, B., Metal ion-induced activation of molecular oxygen in pigmented polymers, Biochem. Biophys. Acta, 883:41-45, 1986.
76. Archibald, F. S., and Tyree, C., Manganese poisoning and the attack of trivalent manganese upon catecholamines, Arch. Biochem. Biophys., 256:638-650, 1987.
77. Swartz, H. M., Sarna, T., and Zecca, L., Modulation by neuromelanin of the availability and reactivity of metal ions, Ann. Neurol., 32:S69-S75, 1992.
78. Ali, S. F., Duhart, H. M., Newport, G. D., Lipe, G. W., and Slikker, W., Jr., Manganese-induced reactive oxygen species: Comparison between Mn+2 and Mn+3, Neurodegeneration, 4(3):329-334, 1995.
79. Olanow, C. W., Good, P. F., Shinotoh, H., Hewitt, K. A., Vingerhoets, F., Snow, B. J., Beal, M. F., Calne, D. B., and Perl, D. P., Manganese intoxication in the rhesusmonkey: A clinical, imaging, pathologic, and biochemical study, Neurology, 46(2):492-498, 1996.
80. Ambani, L. M., Van Woert, M. H., and Murphy, S., Brain peroxidase and catalase in Parkinson’s disease, Arch. Neuro., l 32:114-118, 1975.
81. Graham, D. G., Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson’s disease, Neurotoxicology, 5(1):83-96, 1984.
82. Donaldson, J., and Barbeau, A., Manganese neurotoxicity: possible clues to the etiology of human brain disorders, in Gabay, S. J., Harris and Ho, B. T., (Eds.): Metal ions in Neurology and Psychiatry, Alan R. Liss Inc., New York, pp. 259-285, 1985.
83. Segura-Aguila, J., and Lind, C., On the mechanism of the Mn3+-induced neurotoxicity of dopamine: Prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase Chem-Bio.l Interact., 72:309-324, 1989.
84. Barbeau, A., Manganese and extrapyramidal disorders, (A critical tribute to Dr. George C. Cotzias), Neurotoxicol., 5:13-36, 1984.
85. Halliwell, B., Oxidants and the central nervous system: Some fundamental questions. Is oxidant damage relevant to Parkinson’s disease, Alzheimer’s disease, traumatic injury and stroke? Acta Neurol., scand. 126:23-33, 1989.
86. Yoritaka, A., Hattori, N., Mori et al, An immunohistochemical study on manganese superoxide dismutase in Parkinson’s disease, J. Neurol. Sci., 148:181-186, 1997.
87. Radunovic, A., Porto, W. G., Zeman, S., and Leigh, P. N., Increased mitochondrial superoxide dismutase activity in Parkinson’s disease but not amyotrophic lateral sclerosis motor cortex, Neurosci. Lett., 239:105-108, 1997.
88. Shimoda-Matsubayashi, S., Hattori, T., Matsumine, H. et al, Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson’s disease and control, Neurology, 49:1257-1262, 1997.
89. Feldman, R. G., Manganese as a possible ecoetiologic factor in Parkinson’s disease, Ann. N.Y. Acad. Sci., 648:266-267, 1992.
90. Mena, I., Court, J., Fuezalida, S. et al, Modification of chronic manganese poisoning: Treatment with L-dopa or 5-OH tryptophane, N. Eng. J. Med., 282(1):5-10, 1970.
91. Rosenstock, H. A., Simons, D. G., and Meyer, J. S., Chronic manganism. Neurologic and laboratory studies during treatment with levodopa, JAMA, 217:1354-1359, 1971.
92. Greenhouse, A. H., Manganese Intoxication in the United States. Trans. Am. Neurol. Assoc., 96:248-249, 1971.
93. Cook, D. G., Fahn, S., and Brait, K. A., Chronic manganese intoxication, Arch. Neurol., 30:59-64, 1974
94. Huang, C., Lu, C., Chu, N., Hochberg, F, et al, Progression after chronic manganese exposure, Neurology, 43:1479-1482, 1993.
95. Calne, D. B., Chu, N. S., Huang, C. C., Lu, C. S., Olanow, W., Manganism and idiopathic parkinsonism: Similarities and differences, Neurology, 44(9):1583-1586, 1994.
96. Lu, C. S., Huang, C. C., Chu, N. S., Calne, D. B., Levodopa failure in chronic manganism, Neurology, 44(9):1600-1602, 1994.
97. Wolters, E., Huang, C. C., Clark, C., Peppard, R. F., Okada, J., Chu, N. S., Adam, M. J., Ruth, T. J., Li, D., and Calne, D. B., Positron Emission Tomography in manganese intoxication, Ann. Neurol., 26:647-651, 1989.
98. Tanner, C. M., and Langston, J. W., Do environmental toxins cause Parkinson’s disease? A critical review, Neurology, 40(3):17-30, 1990.
99. Galvani, P., Fumagalli, P., and Santagostino, A., Vulnerability of mitochondrial complex I in PC12 cells exposed to manganese, Euro. J. Pharmacol., 293(4):377-383, 1995.
100. Rodier, J., Manganese poisoning in Moroccan miners, Brit. J. Ind. Med., 12:21-35, 1955.
101. Penalver, R., Diagnosis and treatment of manganese intoxication, Arch. Ind. Health, 16:64-66, 1957.
102. Mena, I., Marin, O., Fuenzalida, S., and Cotzias, G. C., Chronic manganese poisoning: Clinical picture and manganese turnover, Neurology, 17:128-136, 1967.
103. Chandra, S. V., Neurological consequences of manganese imbalance, in Dreosti, i.e., Smith, R. M., (eds), Neurobiology of the Trace Elements, Vol. 2: Neurotoxicology and Neuropharmacology. Humana Press, Clifton, pp. 167-196, 1983.
104. Menegon, A., Board, P. G., Blackburn, A. C., Mellick, G. D., Le Couteur, D. G., Parkinson’s disease, pesticides, and glutathione transferase polymorphisms, Lancet, 352:1344-1246, 1998.
105. Savolainen, K. M., Loikkanen, J., Eerikainen, S., Naarala, J., Glutamte-stimulated ROS production in neuronal cultures: Interaction with lead and cholinergic system, Neurotoxicology, 19:669-674, 1998.
106. Smargiassi, A., Mutti, A., De Rosa, A., De Palma, G., Negrotti, A., Calzetti, S., A case-control study of occupational and environmental risk factors for Parkinson’s disease in the Emilia-Romagna region of Italy, Neurotoxicology, 19(4-5):709-712, 1998.
107. Priyadarshi, A., Khuder, S. A., Schaub, E. A., Shrivastava, S., A meta-analysis of Parkinson’s disease and exposure to pesticides, Neurotoxicology, 21(4):435-440, 2000.
108. Calne, S., Schoenberg, B., Martin, W., Uitti, R. J., Spencer, P., Calne, D. B., Familial Parkinson’s disease: Possible role of environmental factors, Can. J. Neurol. Sci., 14(3):303-305, 1987.
109. Logroscino, G., Marder, K., Cote, L., Tang, M. X., Shea, S., Mayeux, R., Dietary lipids and antioxidants in Parkinson’s disease: A population-based, case-control study, Ann. Neurol., 39(1):89-94, 1996.
110. Kuopio, A.M., Marttila, R. J., Helenius, H., Rinne, U. K., Changing epidemiology of Parkinson’s disease in southwestern Finland, Neurology, 52:302-308, 1999.
111. Rajput, A. H., Offord, K. P., Beard, C. M., Kurland, L. T:, Epidemiology of Parkinsonism: Incidence, classification, and mortality, Ann. Neurol., 16:278-282, 1984.
112. McCann, S. J., LeCouteur, D. G., Green, A. C., Brayne, C., Johnson, A. G., Chan, D., McManus, M. E., Pond, S. M.,The epidemiology of Parkinson’s disease in an Australian population, Neuroepidemiology, 17(6):310-317, 1998.
113. Pezzoli, G., Canesi, M., Antonini, A., Righini, A., Perbellini, L., Barichella, M., Mariani, C. B., Tenconi, F., Tesei, S., Zecchinelli, A., Leenders, K. L., Hydrocarbon exposure and Parkinson’s disease, Neurology, 55(5):667-673, 2000.
114. Racette, B. A., McGee-Minnich, L., Moerlein, S. M., Mink, J. W., Videen, T. O., Perlmutter, J. S., Weldingrelated parkinsonism: Clinical features, treatment, and pathophysiology, Neurology, 56(1):8-13, 2001.
115. Martin, W. R., Ye, F. Q., Allen P. S., Increasing striatal iron content associated with normal aging, Mov Disord., 13(2):281-286, 1998.
116. Anglade, P., Vyas, S., Hirsch, E. C., Agid, Y., Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging, Histol. Histopathol., 12(3): 603-610, 1997.
117. Kessler, I. I., Epidemiologic studies of Parkinson’s disease, II, A hospital-based survey, Am. J. Epidemiol., 95(4):308-318, 1972a.
118. Kessler, I. I., Epidemiologic studies of Parkinson’s disease, 3, A community-based survey, Am. J. Epidemiol., 96(4):242-254, 1972b.
119. Fitzmaurice, P. S., Ang, L., Guttman M., Rajput, A. H., Furukawa, Y., Kish, S. J., Nigral glutathione deficiency is not specific for idiopathic Parkinson’s disease, Mov. Disord. 18(9):969-976, 2003.
120. Thiruchelvam, M., McCormack, A., Richfield, E. K., Baggs, R. B., Tank, A.W., Di Monte, D.A., Cory-Slechta, D. A., Age-related irreversible progressivenigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson’s disease phenotype. Eur. J. Neurosci., 18(3):589-600, 2003.
121. Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., Andersen, J. K., Glutathione, iron and Parkinson’s disease, Biochem Pharmacol., 64(5-6):1037-1048, 2002.
122. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., DiMonte, D., Volitaskis, I., Ellerby, L., Cherny, R. A., Bush, A. I., Andersen, J. K., Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson’s disease, Neuron., 37(6):899-909, 2003.
123. Dekker, M. C., Giesbergen, P. C., Njajou, O. T., van Swieten, J. C., Hofman, A., Breteler, M. M., van Duijn, C. M., Mutations in the hemochromatosis gene (HFE), Parkinson’s disease and parkinsonism, Neurosci Lett., 348(2):117-119, 2003.
124. Gotz, M. E., Double, K., Gerlach, M., Youdim, M. B., Riederer, P., The relevance of iron in the pathogenesis of Parkinson’s disease, Ann. NY Acad. Sci., 1012:193-208, 2004.
125. Faucheux, B. A., Martin, M. E., Beaumont, C., Hauw J. J., Agid, Y., Hirsch, E. C., Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease, J. Neurochem. 86(5):1142-1148, 2003.